Information Provided By: 
Fly News Breaks for May 1, 2018
ALNY, DRNA
May 1, 2018 | 07:29 EDT
H.C. Wainwright analyst Ed Arce believes resolving all pending litigation with Alnylam (ALNY) removes an overhang on shares of Dicerna Pharmaceuticals (DRNA). The litigation with Alnylam had created an overhang on business development opportunities, likely causing perhaps three or more potential partners to decline a deal at the time, Arce tells investors in a research note. With the settlement, the analyst believes potential partners are likely to return to the negotiating table. He keeps a Neutral rating on Dicerna with a $12 price target.
News For DRNA;ALNY From the Last 2 Days
There are no results for your query DRNA;ALNY
